Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
iX Biopharma Ltd. ( (SG:42C) ) has shared an announcement.
iX Biopharma Ltd. reported a 39% revenue growth to $3.7 million in the first half of 2025, primarily driven by increased sales in specialty pharmaceuticals and nutraceuticals, including strong demand for medicinal cannabis products in Australia. The company also improved its operational efficiency by reducing operating expenses and headcount, which led to a 33% reduction in operating cash burn and a 20% decrease in adjusted EBITDA loss, signaling progress towards profitability.
More about iX Biopharma Ltd.
iX Biopharma Ltd. operates in the pharmaceutical industry, focusing on specialty pharmaceuticals and nutraceuticals. The company is known for its medicinal cannabis products and flagship nutraceutical products, SL-NAD+ and LumeniX, with a market focus primarily in Australia.
YTD Price Performance: 15.00%
Average Trading Volume: 182,897
Technical Sentiment Consensus Rating: Buy
Current Market Cap: S$19.35M
For an in-depth examination of 42C stock, go to TipRanks’ Stock Analysis page.